Resources for Patients and their Families

Gefitinib in Treating Patients With Malignant Mesothelioma

Brief Summary

Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant mesothelioma

Tracking Information
First Received DateOctober 11, 2001
Last Changed DateJanuary 15, 2013
Start DateSeptember 2001
Actual Primary Completion DateFebruary 2006
Primary Outcome Measures

Percentage of patients who remain failure-free [Time Frame: Time between the initiation of treatment and initial failure (disease progression, relapse, death), assessed up to 3 months]

Secondary Outcome Measures

Tumor response rate [Time Frame: Up to 4 years]

Toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 [Time Frame: Up to 4 years]

Overall survival [Time Frame: Up to 4 years]

Failure-free survival within patient subgroups defined in terms of epidermal growth factor receptor (EGFR) overexpression and cyclooxygenase-2 (COX-2) expression [Time Frame: Up to 4 years]

Descriptive Information
PhasePhase 2
Study TypeInterventional
  • Advanced Malignant Mesothelioma
  • Epithelial Mesothelioma
  • Recurrent Malignant Mesothelioma
  • Sarcomatous Mesothelioma
  • Drug: gefitinib
  • Other: laboratory biomarker analysis
Study Arms / Comparison Groups1 / 0
Detailed Description


I. Determine the activity of gefitinib, in terms of failure-free survival, in patients with malignant mesothelioma.

II. Determine the response rate in patients treated with this drug. III. Determine the toxicity of this drug in these patients. IV. Determine the overall survival of patients treated with this drug. V. Determine whether overexpression of epidermal growth factor receptor and expression of cyclo-oxygenase-2 can predict the effectiveness of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2 months for 1 year and then every 6 months for up to 3 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 7-10 months.

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment40
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Histologically confirmed malignant mesothelioma that is not amenable to curative surgery or radiotherapy

- Epithelial, sarcomatoid, or mixed subtype

- Any site of origin (including, but not limited to, the pleura, peritoneum, pericardium, or tunica vaginalis) allowed

- Measurable disease, defined as lesions that can be accurately measured in at least 1 dimension (longest diameter) as at least 20 mm with conventional techniques or at least 10 mm with spiral CT scan

- Must be outside prior radiation port

- Lesions not considered measurable include the following:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Inflammatory breast disease

- Lymphangitis cutis/pulmonis

- Abdominal masses not confirmed and followed by imaging techniques

- Cystic lesions

- No known brain metastases

- Performance status - CTC 0-1

- Granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT no greater than 2.5 times ULN

- Creatinine no greater than 1.5 times ULN

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No other concurrent active malignancy except nonmelanoma skin cancer

- Disease considered not currently active if completely treated with less than a 30% risk for relapse

- No other concurrent uncontrolled illness

- No ongoing or active infection

- No psychiatric illness or social situation that would preclude study compliance

- No prior epidermal growth factor receptor-inhibitor therapy

- Prior intrapleural cytotoxic or sclerosing agents (including bleomycin) allowed

- No prior systemic cytotoxic chemotherapy for malignant mesothelioma

- No concurrent chemotherapy

- At least 1 week since prior CYP3A4 inducers (e.g., dexamethasone, glucocorticoids, progesterone)

- No concurrent CYP3A4 inducers (e.g., dexamethasone)

- No concurrent hormonal therapy (e.g., tamoxifen) except steroids for adrenal failure or hormones for non disease-related conditions (e.g., insulin for diabetes)

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy

- No concurrent radiotherapy, including for palliation

- See Disease Characteristics

- At least 2 weeks since prior major surgery

- At least 1 week since other prior CYP3A4 inducers (e.g., carbamazepine, ethosuximide, griseofulvin, nafcillin, nelfinavir mesylate, nevirapine, oxcarbazepine, phenobarbital, phenylbutazone, phenytoin, primidone, rifabutin, rifampin, rofecoxib, St. John's Wort, sulfadimidine, sulfinpyrazone, or troglitazone)

- No other concurrent CYP3A4 inducers

- No concurrent CYP3A4 substrates or inhibitors

- No other concurrent investigational agent

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent chlorpromazine, amiodarone, or chloroquine

Administrative Information
Responsible PartySponsor
SponsorNational Cancer Institute (NCI)
Verification DateJanuary 2013
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog



Fall 2018 Mesothelioma Cancer Alliance Scholarship Winner Darwin Arias

Prognosis of Mesothelioma Without Treatment

Asbestos Is No Laughing Matter

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: